Basilea 从辉瑞公司赚取了 $1.25M，因为 Cresemba 在亚太地区和中国的销售量超过了里程碑。 Basilea earns $1.25M from Pfizer as Cresemba sales in APAC and China exceed milestone.
Basilea Pharmaceutica 宣布，辉瑞在亚太地区和中国的抗真菌药物 Cresemba（艾沙康唑）的销售超过了里程碑门槛，导致向 Basilea 支付了 125 万美元。 Basilea Pharmaceutica announced that Pfizer's sales of the antifungal drug Cresemba (isavuconazole) in the Asia Pacific region and China exceeded a milestone threshold, resulting in a $1.25 million payment to Basilea. 这是今年第四次里程碑式付款,凸显了克里森巴公司不断增长的需求。 This is the fourth milestone payment this year, highlighting Cresemba's growing demand. 在70多个国家,包括美国和欧盟,Cresemba在70多个国家获得批准,对侵入性霉菌感染有效,年销售额增加了20%。 Approved in over 70 countries, including the U.S. and EU, Cresemba is effective against invasive mold infections and has seen a 20% annual sales increase.